Role of body mass index as a predictor of dupilumab efficacy in patients with severe chronic rhinosinusitis with nasal polyps.

IF 2.1 4区医学 Q2 OTORHINOLARYNGOLOGY

Acta Otorhinolaryngologica Italica Pub Date : 2025-02-01 DOI:10.14639/0392-100X-N2841

Letizia Nitro, Eugenio De Corso, Marco Borin, Alberto Maria Saibene, Flavio Arnone, Francesco Ferella, Giulia Gramellini, Alessandro Cantiani, Gabriele De Maio, Camilla Spanu, Alberto Giulio Dragonetti, Giovanni Felisati, Carlotta Pipolo

{"title":"Role of body mass index as a predictor of dupilumab efficacy in patients with severe chronic rhinosinusitis with nasal polyps.","authors":"Letizia Nitro, Eugenio De Corso, Marco Borin, Alberto Maria Saibene, Flavio Arnone, Francesco Ferella, Giulia Gramellini, Alessandro Cantiani, Gabriele De Maio, Camilla Spanu, Alberto Giulio Dragonetti, Giovanni Felisati, Carlotta Pipolo","doi":"10.14639/0392-100X-N2841","DOIUrl":null,"url":null,"abstract":"Objective: Response to dupilumab for chronic rhinosinusitis with nasal polyps, albeit almost always excellent, is still not predictable. Our study focuses on the role of body mass index (BMI) on the efficacy of dupilumab.Methods: We present a retrospective multicentre study of 106 patients on dupilumab, stratified in 3 subgroups of BMI. The main therapeutic outcomes investigated were Nasal Polyp Score (NPS), Sino-Nasal-Outcome Test - 22 (SNOT-22), Sniffin' Sticks Identification test and visuo-analogical scale, and the different timing of response, according to De Corso et al. criteria.Results: Dupilumab treatment led to a progressive improvement for all outcomes at all time points. Comparing the different metabolic subgroups, a late response in terms of decrease in NPS was observed only in 3 obese patients. A significant decrease was also found in SNOT-22 score at 6 and 12 months, which was less marked in overweight/obese patients.Conclusions: Our study confirmed the efficacy of dupilumab in each BMI subgroup. However, the efficacy seems to follow different timing with respect to patients' BMI. Our data suggest that patients with a compromised metabolic state present more severe disease at baseline and a possibly delayed response to dupilumab.","PeriodicalId":6890,"journal":{"name":"Acta Otorhinolaryngologica Italica","volume":"45 1","pages":"28-38"},"PeriodicalIF":2.1000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924193/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Otorhinolaryngologica Italica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14639/0392-100X-N2841","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Response to dupilumab for chronic rhinosinusitis with nasal polyps, albeit almost always excellent, is still not predictable. Our study focuses on the role of body mass index (BMI) on the efficacy of dupilumab.

Methods: We present a retrospective multicentre study of 106 patients on dupilumab, stratified in 3 subgroups of BMI. The main therapeutic outcomes investigated were Nasal Polyp Score (NPS), Sino-Nasal-Outcome Test - 22 (SNOT-22), Sniffin' Sticks Identification test and visuo-analogical scale, and the different timing of response, according to De Corso et al. criteria.

Results: Dupilumab treatment led to a progressive improvement for all outcomes at all time points. Comparing the different metabolic subgroups, a late response in terms of decrease in NPS was observed only in 3 obese patients. A significant decrease was also found in SNOT-22 score at 6 and 12 months, which was less marked in overweight/obese patients.

Conclusions: Our study confirmed the efficacy of dupilumab in each BMI subgroup. However, the efficacy seems to follow different timing with respect to patients' BMI. Our data suggest that patients with a compromised metabolic state present more severe disease at baseline and a possibly delayed response to dupilumab.

查看原文本刊更多论文

体重指数在严重慢性鼻窦炎伴鼻息肉患者中作为dupilumab疗效预测因子的作用

目的：dupilumab治疗慢性鼻窦炎伴鼻息肉的疗效虽然几乎总是很好，但仍不可预测。我们的研究重点是身体质量指数（BMI）在dupilumab疗效中的作用。方法：我们对106例使用杜匹单抗的患者进行了一项回顾性多中心研究，根据BMI分为3个亚组。根据De Corso等人的标准，研究的主要治疗结果为鼻息肉评分（NPS）、鼻结果测试-22 （SNOT-22）、嗅嗅棒识别测试和视觉类比量表，以及不同的反应时间。结果：Dupilumab治疗在所有时间点的所有结果都有进行性改善。比较不同的代谢亚组，仅在3名肥胖患者中观察到NPS降低的延迟反应。在6个月和12个月时，SNOT-22评分也显著下降，超重/肥胖患者的下降幅度较小。结论：我们的研究证实了dupilumab在每个BMI亚组中的疗效。然而，疗效似乎随患者BMI的不同而不同。我们的数据表明，代谢状态受损的患者在基线时表现出更严重的疾病，并且可能延迟对dupilumab的反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Otorhinolaryngologica Italica OTORHINOLARYNGOLOGY-

CiteScore

3.40

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Acta Otorhinolaryngologica Italica first appeared as “Annali di Laringologia Otologia e Faringologia” and was founded in 1901 by Giulio Masini. It is the official publication of the Italian Hospital Otology Association (A.O.O.I.) and, since 1976, also of the Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale (S.I.O.Ch.C.-F.). The journal publishes original articles (clinical trials, cohort studies, case-control studies, cross-sectional surveys, and diagnostic test assessments) of interest in the field of otorhinolaryngology as well as clinical techniques and technology (a short report of unique or original methods for surgical techniques, medical management or new devices or technology), editorials (including editorial guests – special contribution) and letters to the Editor-in-Chief. Articles concerning science investigations and well prepared systematic reviews (including meta-analyses) on themes related to basic science, clinical otorhinolaryngology and head and neck surgery have high priority.